Health

Lilly CEO Says Weight-Loss Drug Will Be Off Shortage Soon

End of shortage could threaten billion-dollar copycat industry
Shares of Hims fell as much as 16% following the comments

The FDA’s shortage list says two doses of Lilly’s drug used for weight loss and two doses for diabetes are only available in limited quantities through July.
Photographer: Shelby Knowles/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Gillian Tan and Damian Garde

August 1, 2024 at 12:43 PM EDT

Updated on

August 1, 2024 at 2:24 PM EDT

This article is for subscribers only.

Eli Lilly & Co. expects its blockbuster weight-loss drug to officially come out of shortage in the US in the coming days, the company’s chief executive officer said, threatening the billion-dollar industry of copycat versions of the in-demand drugs.

Lilly’s drug, sold for weight loss as Zepbound, will cease to be in shortage “very soon,” CEO David Ricks said in an interview in Paris on Thursday. “I think actually today or tomorrow we plan to exit that process.”